BRIEF published on 12/04/2025 at 07:35, 21 hours 49 minutes ago ADOCIA Secures €10 Million Fundraising for Growth Shares Fundraising Investment Biopharmaceutical ADOCIA
PRESS RELEASE published on 12/04/2025 at 07:30, 21 hours 54 minutes ago Inside Information / Other news releases Adocia successfully completes a €10 million fundraising through a capital increase. Proceeds to support technology platform development. Cash runway extended to 2027 Fundraising Capital Increase Cash Runway ADOCIA Technology Platforms
BRIEF published on 11/12/2025 at 07:35, 22 days 21 hours ago Adocia Progresse with AdoXLongTM and BioChaperone® Diabetes Patent ADOCIA BioChaperone® AdoXLongTM
PRESS RELEASE published on 11/12/2025 at 07:30, 22 days 21 hours ago Inside Information / Other news releases Adocia files patent for AdoXLongTM platform to extend duration of action for peptides in diabetes and obesity treatment. BioChaperone® platform updated with feasibility studies Obesity Treatment Diabetes Treatment Patent Filing ADOCIA AdoXLongTM
BRIEF published on 10/21/2025 at 10:47, 1 month 14 days ago Crossing thresholds at ADOCIA Warrants Actions Crossing Thresholds ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 1 month 20 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 1 month 20 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 07/25/2025 at 08:50, 4 months 10 days ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
PRESS RELEASE published on 07/25/2025 at 08:45, 4 months 10 days ago Inside Information / Other news releases Adocia and Tonghua Dongbao announce positive Phase 3 results of Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in Type 2 Diabetes. Significant HbA1c reduction and improved post-meal blood glucose levels compared to Humalog® Type 2 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 04/04/2025 at 11:21, 8 months ago Vester Finance reduces its stake in ADOCIA Voting Rights Actions Threshold Crossing ADOCIA Vester Finance
Published on 12/05/2025 at 02:35, 2 hours 49 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 24 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 19 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 24 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 54 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 33 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 59 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 9 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 14 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 24 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 39 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 40 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 23 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
